JP2022524576A - 過活動膀胱を処置するためのビベグロンの使用 - Google Patents

過活動膀胱を処置するためのビベグロンの使用 Download PDF

Info

Publication number
JP2022524576A
JP2022524576A JP2021545837A JP2021545837A JP2022524576A JP 2022524576 A JP2022524576 A JP 2022524576A JP 2021545837 A JP2021545837 A JP 2021545837A JP 2021545837 A JP2021545837 A JP 2021545837A JP 2022524576 A JP2022524576 A JP 2022524576A
Authority
JP
Japan
Prior art keywords
subject
vibeglon
placebo
subjects
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021545837A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524576A5 (https=
Inventor
エヌ ムッド ジュニア ポール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Urovant Sciences GmbH
Original Assignee
Urovant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urovant Sciences GmbH filed Critical Urovant Sciences GmbH
Publication of JP2022524576A publication Critical patent/JP2022524576A/ja
Publication of JP2022524576A5 publication Critical patent/JP2022524576A5/ja
Priority to JP2025018962A priority Critical patent/JP2025084777A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021545837A 2019-03-18 2020-03-18 過活動膀胱を処置するためのビベグロンの使用 Pending JP2022524576A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025018962A JP2025084777A (ja) 2019-03-18 2025-02-07 過活動膀胱を処置するためのビベグロンの使用

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201962820230P 2019-03-18 2019-03-18
US62/820,230 2019-03-18
US201962830302P 2019-04-05 2019-04-05
US62/830,302 2019-04-05
US201962842435P 2019-05-02 2019-05-02
US62/842,435 2019-05-02
US201962885767P 2019-08-12 2019-08-12
US62/885,767 2019-08-12
US201962897019P 2019-09-06 2019-09-06
US62/897,019 2019-09-06
US201962904429P 2019-09-23 2019-09-23
US62/904,429 2019-09-23
PCT/IB2020/052484 WO2020188505A1 (en) 2019-03-18 2020-03-18 Use of vibegron to treat overactive bladder

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025018962A Division JP2025084777A (ja) 2019-03-18 2025-02-07 過活動膀胱を処置するためのビベグロンの使用

Publications (2)

Publication Number Publication Date
JP2022524576A true JP2022524576A (ja) 2022-05-09
JP2022524576A5 JP2022524576A5 (https=) 2023-04-03

Family

ID=70166082

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021545837A Pending JP2022524576A (ja) 2019-03-18 2020-03-18 過活動膀胱を処置するためのビベグロンの使用
JP2025018962A Pending JP2025084777A (ja) 2019-03-18 2025-02-07 過活動膀胱を処置するためのビベグロンの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025018962A Pending JP2025084777A (ja) 2019-03-18 2025-02-07 過活動膀胱を処置するためのビベグロンの使用

Country Status (14)

Country Link
US (1) US20230027066A1 (https=)
EP (1) EP3941473A1 (https=)
JP (2) JP2022524576A (https=)
KR (2) KR20210142004A (https=)
CN (2) CN121489955A (https=)
AU (2) AU2020243514A1 (https=)
BR (1) BR112021017198A2 (https=)
CA (1) CA3129024A1 (https=)
IL (1) IL285910A (https=)
MX (1) MX2021009488A (https=)
PH (1) PH12021551975A1 (https=)
SG (1) SG11202108810YA (https=)
TW (2) TW202102221A (https=)
WO (1) WO2020188505A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3634420A1 (en) 2017-06-06 2020-04-15 Urovant Sciences GmbH Use of vibegron to treat overactive bladder
SG11202103662VA (en) 2018-12-05 2021-06-29 Urovant Sciences Gmbh Vibegron for the treatment of overactive bladder symptoms
TW202245781A (zh) * 2021-02-16 2022-12-01 瑞士商優洛凡特科學公司 用維貝格龍（ｖｉｂｅｇｒｏｎ）治療心臟衰竭之方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018224990A1 (en) * 2017-06-06 2018-12-13 Urovant Sciences Gmbh Dosing of vibegron for treatment of overactive bladder
WO2018224989A1 (en) * 2017-06-06 2018-12-13 Urovant Sciences Gmbh Use of vibegron to treat overactive bladder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
ES2584427T3 (es) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Proceso para la preparación de agonistas beta 3 y productos intermedios
WO2013062881A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
RS59402B1 (sr) 2013-03-15 2019-11-29 Merck Sharp & Dohme Postupak za pripremu beta 3 agonista i međuproizvoda
JP6197971B1 (ja) * 2016-04-22 2017-09-20 小野薬品工業株式会社 Ｋｃｎｑ２〜５チャネル関連疾患の予防および／または治療剤
US20170348288A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder
US10057209B2 (en) * 2016-07-28 2018-08-21 Qualcomm Incorporated Time-sequenced multi-device address assignment
EP3583905A1 (en) * 2018-06-20 2019-12-25 Arthrex Inc Percutaneous targeting device

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018224990A1 (en) * 2017-06-06 2018-12-13 Urovant Sciences Gmbh Dosing of vibegron for treatment of overactive bladder
WO2018224989A1 (en) * 2017-06-06 2018-12-13 Urovant Sciences Gmbh Use of vibegron to treat overactive bladder

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EUROPEAN UROLOGY, vol. 73, JPN6024009540, 2018, pages 783 - 790, ISSN: 0005280853 *
EUROPEAN UROLOGY, vol. 75, JPN6024009542, 25 October 2018 (2018-10-25), pages 274 - 282, ISSN: 0005280855 *
VALUE IN HEALTH, vol. 21, JPN6024009541, 2018, pages 267 - 268, ISSN: 0005280854 *

Also Published As

Publication number Publication date
CN113840607A (zh) 2021-12-24
SG11202108810YA (en) 2021-10-28
AU2020243514A1 (en) 2021-08-26
AU2025256180A1 (en) 2025-11-13
MX2021009488A (es) 2021-09-21
TW202506129A (zh) 2025-02-16
WO2020188505A1 (en) 2020-09-24
CN121489955A (zh) 2026-02-10
EP3941473A1 (en) 2022-01-26
JP2025084777A (ja) 2025-06-03
BR112021017198A2 (pt) 2021-11-16
CA3129024A1 (en) 2020-09-24
TW202102221A (zh) 2021-01-16
PH12021551975A1 (en) 2022-07-04
IL285910A (en) 2021-10-31
KR20210142004A (ko) 2021-11-23
KR20260049872A (ko) 2026-04-14
US20230027066A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
JP2021506924A (ja) うつ病の治療のためのエスケタミン
JP2026050474A (ja) Ｎｍｄａ拮抗薬の副作用の低減
JP2025084777A (ja) 過活動膀胱を処置するためのビベグロンの使用
JP2025032143A (ja) 良性前立腺肥大症の男性の過活動膀胱症状を治療するためのビベグロンの使用
US20230270738A1 (en) Methods of treating agitation associated with alzheimer's disease
WO2024216046A1 (en) Methods of treating anhedonia
WO2024216061A1 (en) Methods of treating depression and anhedonia
US20050009862A1 (en) Method for promoting uninterrupted sleep by administration of trospium chloride
TW202333705A (zh) 治療與阿茲海默症相關之激越的方法
HK40126413A (en) Use of vibegron to treat overactive bladder symptoms in men with benign prostatic hyperplasia
Malavige et al. Premature ejaculation and its management
EP4683634A1 (en) Treatment of scleroderma
WO2024196957A1 (en) Method for treating l-dopa-induced dyskinesia using befiradol
EA052961B1 (ru) Вибегрон для лечения симптомов гиперактивного мочевого пузыря
Ellsworth Pharmacotherapy Update on the Treatment of Overactive Bladder Syndrome: Focus on Fesoterodine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211006

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240312

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240607

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241008